Holen Sie sich die Stockscreener-App
1.49
2.93%
-0.045
Handel nachbörslich:
1.53
0.04
+2.68%
Okyo Pharma Limited Aktie (OKYO) Neueste Nachrichten
OKYO Pharma CSO buys shares - Proactive financial news
OKYO Pharma CSO purchases additional shares at $1.49 By Investing.com - Investing.com Nigeria
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer - The Manila Times
OKYO Pharma (Nasdaq: OKYO) CSO boosts stake, plans Phase 3 NCP trial - Stock Titan
OKYO Pharma scientist's holdings reach 20,030 shares after purchase - Stock Titan
OKYO Pharma Ltd (OKYO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OKYO Pharma to participate in BTIG Biotechnology Conference 2026 - Proactive financial news
OKYO Pharma Ltd (OKYO) Cash Flow - TradingKey
OKYO Pharma (NASDAQ:OKYO) Is In A Good Position To Deliver On Growth Plans - simplywall.st
OKYO Pharma to Participate in BTIG Biotechnology Conference 2026 - Quiver Quantitative
OKYO Pharma (Nasdaq: OKYO) plans Phase 3 NCP trial, joins BTIG conference - Stock Titan
OKYO Pharma plans 111-patient Phase 3 corneal pain trial - Stock Titan
OKYO Pharma Ltd (OKYO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OKYO Pharma Ltd (OKYO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OKYO Pharma Ltd (OKYO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
OKYO Pharma Ltd (OKYO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OKYO Pharma Ltd (OKYO) Institutional Confidence - TradingKey
OKYO Pharma Ltd (OKYO) Valuation: PE, PB & Fair Value Analysis - TradingKey
OKYO Pharma Limited Revenue Breakdown – GETTEX:OK11 - TradingView
OKYO|OKYO Pharma Ltd|Price:1.630|Chg%:+0.080 - TradingKey
TradingKey - TradingKey
OKYO Pharma outlines path to phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain - Ophthalmology Times Europe
OKYO|OKYO Pharma Ltd|Price:1.550|Chg%:+0.070 - TradingKey
Form 4 OKYO Pharma Ltd For: 24 July By Investing.com - Investing.com South Africa
OKYO Pharma (OKYO) grants 3,500 shares to chief development officer - Stock Titan
OKYO Pharma CEO Robert Dempsey Acquires 15,000 Shares at $1.54 Ahead of Phase 3 Trial Launch - Kalkine Media
OKYO Pharma director buys 5,000 shares at $1.48, increasing his stake to 35,201 shares. - Pluang
OKYO Pharma Director John Brancaccio Purchases 5,000 Shares on Nasdaq - Quiver Quantitative
OKYO Pharma (Nasdaq: OKYO) director ups stake with 5,000-share purchase - Stock Titan
OKYO Pharma Director's Holding Reaches 35,201 Shares - Stock Titan
OKYO Pharma CEO purchases 15,000 shares at $1.54 each - Investing.com
OKYO Pharma CEO purchases 15,000 shares at $1.54 each By Investing.com - Investing.com South Africa
OKYO Pharma Announces Purchase of Shares by Chief Executive Officer - The Manila Times
OKYO Pharma (Nasdaq: OKYO) CEO purchases 15,000 company shares - Stock Titan
OKYO Pharma Plans Global Phase 3 Trial for About 111 Patients - Stock Titan
OKYO Pharma says CEO purchased 15,000 shares - Proactive financial news
OKYO Pharma director Brancaccio raises stake to 35,201 shares after $1.48 purchase - Bitget
OKYO Pharma executive purchases 3,500 shares at $1.40 each By Investing.com - Investing.com Australia
OKYO Pharma grants CMO 20,000 common shares | OKYO Insider Trading - Stock Titan
OKYO Pharma Chairman Boosts Stake to Over 20% Ahead of Phase 3 Trial - TipRanks
OKYO Pharma Chairman buys 22,500 shares, raisin... - Pluang
OKYO Pharma (Nasdaq: OKYO) chair buys more shares, now owns 20.55% - Stock Titan
OKYO Pharma LTD - Via Ritzau
OKYO Pharma executive purchases 3,500 shares at $1.40 each - Investing.com India
OKYO Pharma CMO purchases 20,000 shares at $1.40 each By Investing.com - Investing.com South Africa
OKYO Pharma Chief Development Officer Gary S. Jacob Increases Shareholding with Open-Market Purchase - Quiver Quantitative
OKYO Pharma (Nasdaq: OKYO) director adds 3,500 shares at $1.40 - Stock Titan
OKYO Pharma director lifts holding to 112,420 shares - Stock Titan
OKYO Pharma announces chief medical officer share purchase - Proactive financial news
OKYO Pharma CMO Boosts Stake Ahead of Planned Global Phase 3 Trial - TipRanks
OKYO Pharma CMO purchases 20,000 shares at $1.40 each - Investing.com
OKYO Pharma Announces Purchase of Shares by Chief Medical Officer - The Manila Times
OKYO Pharma (Nasdaq: OKYO) CMO purchases 20,000 shares on market - Stock Titan
OKYO Pharma’s Chief Medical Officer Acquires 20,000 Shares at $1.40 Ahead of Phase 3 Trial Launch - Kalkine Media
OKYO Pharma Plans Phase 3 Trial for Single-Dose Eye Pain Drug - Stock Titan
OKYO Pharma CDO Jacob lifts stake to 112,420 shares with 3,500-share buy at $1.4 - Bitget
OKYO Pharma Ltd (OKYO) director awarded 25,000 shares of common stock - Stock Titan
1.84%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):